Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTS,S/AS01B and ChAd63/MVA ME-TRAP Malaria Vaccine Study
NCT01883609Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Sep 2013
- Primary completion
- Aug 2014
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ChAd63 ME-TRAP, MVA ME-TRAP and RTS,S in malaria (4 arms), sponsored by University of Oxford. Primary endpoints: Efficacy against malaria sporozoite challenge at 12 months and Safety of immunization regimen at 12 months. Started Sep 2013; status: completed.
02
Drugs
ChAd63 ME-TRAPMVA ME-TRAPRTS,S
03
Conditions
malaria
Beyond the preview
Go deeper on NCT01883609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883609.